Atacicept Clinical Development & Regulatory Milestones - Vera Therapeutics anticipates a US market launch of atacicept for IgAN in 2026, pending FDA approval[8, 9] - Phase 3 ORIGIN trial of atacicept achieved its primary endpoint, demonstrating a statistically significant 42% reduction in proteinuria (UPCR) compared to placebo at week 36 (p<00001)[43] - In the ORIGIN 3 trial, atacicept showed a 67% reduction in Gd-IgA1 and an 81% resolution of hematuria compared to placebo[48] - Vera Therapeutics plans to submit a BLA for atacicept in Q4 2025[8] Financial Position - As of September 30, 2025, Vera Therapeutics has approximately $497 million in cash, cash equivalents, and marketable securities[11] - Vera Therapeutics has an additional $425 million in non-dilutive capital available through the Oxford Facility[12] IgAN Market & Atacicept Potential - Vera Therapeutics estimates the US IgAN prevalence to be approximately 004% of the US population, or about 160,000 patients[59] - Nephrologists ranked atacicept as the most desired IgAN pipeline agent, with 30% considering it the most desired and 73% ranking it in the top 3[62] Pipeline Expansion - Vera Therapeutics is conducting a Phase 2 PIONEER trial to evaluate atacicept in expanded IgAN populations and anti-PLA2R & anti-nephrin podocytopathies[81]

Third Quarter Earnings Conference Call November 6, 2025 Foward Looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of, and subject to the protection of, the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 ...

Q3 Supplemental Information NOVEMBER 2025 Funko, LLC © 2025 Cautionary Notes This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our future results of operations and financial position, industry dynamics, business strategy and plans and our objectives for fut ...

Financial Performance - Total revenue and non-GAAP operating income for Q3 2025 exceeded guidance[6] - Consumer Banking Suite revenue increased by 34% year-over-year[7] - Non-GAAP operating expenses reflect cost discipline[17] - Q4 2025 total revenue is expected to be between $31 million and $32.5 million, representing a year-over-year increase of 5% at the midpoint[26] - Non-GAAP net income from continuing operations was $5560 thousand for Q3 2025, compared to a loss of $631 thousand in GAAP[35] Revenue Breakdown - Consumer Banking Suite revenue was $12724 thousand in Q3 2025, a 34% increase year-over-year[29] - Mortgage Suite revenue was $17735 thousand in Q3 2025, an 18% decrease year-over-year[29] - Total Software Platform revenue was $30459 thousand in Q3 2025, a 2% decrease year-over-year[29] Market Position - Blend's funded loans as a percentage of HMDA mortgage originations is estimated to be 16-18% in 2025[23] - The company's market share has decreased since 2023 due to churn notices received primarily in 2023 and 2024[24] - Added or expanded 14 customer relationships this quarter, with pipeline up approximately 60% year-over-year[6]

3Q 2025 Results Conference Call and Webcast November 6, 2025 Nasdaq: ZYME | zymeworks.com Legal Disclaimer This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this presentation and the accompanying oral commentary include, but are no ...

THIRD QUARTER 2025 EARNINGS PRESENTATION NASDAQ: TBCH | NOVEMBER 6, 2025 SAFE HARBOR STATEMENT & IMPORTANT INFORMATION Forward-Looking Information and Statements This presentation, including the appendix, includes forward-looking information and statements within the meaning of the federal securities laws. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding assumptions, projections, expectations, targets, intentions or b ...

Financial Performance - Q1 2026 - Revenue reached $2.308 billion, a 21% increase quarter-over-quarter (QoQ) and a 23% increase year-over-year (YoY)[17] - Non-GAAP Gross Margin was 29.9%, up 3.5 percentage points QoQ but down 9 percentage points YoY[6, 17] - Non-GAAP Diluted Net Income per Share was $1.22, a 321% increase QoQ but a 33% decrease YoY[6, 17] - Adjusted Free Cash Flow was $448 million, a 482% increase QoQ and a 399% increase YoY[6, 17] Revenue by End Market - Q1 2026 - Datacenter revenue was $269 million, a 26% increase QoQ[15] - Edge revenue was $1.387 billion, a 26% increase QoQ[15] - Consumer revenue was $652 million, an 11% increase QoQ[15] Capital Expenditure - Total Sandisk Gross CapEx was $387 million, representing 16.8% of net revenue[18] - Total Sandisk Cash CapEx was $40 million, representing 1.7% of net revenue[18] Fiscal Second Quarter Guidance - Revenue is projected to be between $2.55 billion and $2.65 billion[20] - Non-GAAP Gross Margin is expected to be between 41% and 43%[20] - Non-GAAP Diluted Net Income per Share is projected to be between $3.00 and $3.40[20]

3Q 2025 Earnings Presentation November 6, 2025 1 © 2025 Artivion, Inc. FORWARD-LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management's beliefs, expectations, or forecasts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs and expectations about our future revenue ...

Business Highlights - Codexis secured a $37.8 million Supply Assurance Agreement with Merck [7, 15] - The company expects to receive the cash from the Merck agreement by the end of 2025 [7, 15] - Codexis has a cash runway through 2027 [7] - Codexis has 11 customers this year and a pipeline of 40 prospects [7, 13] - The company will sign a lease on a 34,000 square feet multi-purpose GMP facility in the next few weeks [7] Executive Management Transition and Cost Reduction - Codexis is reducing operating expenses by 25% through the elimination of 46 positions [10] - Dr Stephen Dilly will transition to Chairman, and Dr Alison Moore will assume the role of President and CEO [10] Q3 2025 Financial Results - Total revenue for Q3 2025 was $8.6 million, compared to $12.8 million in Q3 2024 [16] - Product gross margin increased to 64% in Q3 2025 from 61% in Q3 2024 [16] - R&D expenses for Q3 2025 were $13.9 million, compared to $11.5 million in Q3 2024 [16] - Net loss for Q3 2025 was $19.6 million, or $0.22 per share, compared to a net loss of $20.6 million, or $0.29 per share, in Q3 2024 [16]

ibex Q1 FY2026 Earnings Call November 6, 2025 Bob Dechant, CEO Built for what's next. Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts, are forward-looking statements. The words "believe," "estimate," "expect," "may," "will" and similar expressions are intended to identify forward-looking statements. Such forward- looking stateme ...